



**Evgen Pharma plc**  
("Evgen", the "Company" or the "Group")

**Change of Name**  
and  
**Change of Company Website**

**Alderley Park, UK - 25 April 2024:** Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, confirms that further to its announcement on 19 March 2024, the Company's change of name to TheraCryf plc and change of AIM ticker to TCF will become effective tomorrow, 26 April 2024.

At the same time the Company notifies shareholders that, pursuant to AIM Rule 26, its corporate website will also change to [www.theracryf.com](http://www.theracryf.com) effective tomorrow.

- Ends -

**Enquiries**

**Evgen Pharma plc**  
Dr Huw Jones, CEO  
Toni Hänninen, CFO  
Dr Helen Kuhlman, CBO

**+44 (0)1625 315 090**  
[enquiries@evgen.com](mailto:enquiries@evgen.com)

**Cavendish Capital Markets (NOMAD and Broker)**  
Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)  
Nigel Birks / Harriet Ward (ECM)

**+44 20 7220 0500**

**Instinctif Partners**  
Melanie Toyne-Sewell / Jack Kincade

**+44 207 457 2020**  
[Evgen@Instinctif.com](mailto:Evgen@Instinctif.com)

**About Evgen Pharma plc**

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead clinical asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands funded by a grant from the Netherlands government and Dutch Cancer Society.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicia SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of \$160.5m and a double-digit royalty on sales.

Evgen recently acquired neuropsychiatry company Chronos Therapeutics Limited, now a wholly owned affiliate of the Company. The acquired assets comprise an orexin-1 antagonist (Ox-1) in late pre-clinical development targeting impulsivity and anxiety disorders and an atypical dopamine transporter inhibitor (DAT) also in late pre-clinical development for

fatigue, e.g. due to long COVID or multiple sclerosis and the orphan condition narcolepsy.

The Company has its headquarters and registered office at Alderley Park,Cheshire.It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: [www.evgen.com](http://www.evgen.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CANIAMITMTITBII